November 26, 2019

Keith Regnante
Chief Financial Officer
Wave Life Sciences Ltd.
7 Straits View #12-00
Marina One East Tower
Singapore 018936

       Re: Wave Life Sciences Ltd.
           Form 10-K for fiscal year ended December 31, 2018
           Filed March 1, 2019
           File No. 001-37627

Dear Mr. Regnante:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comments. In some of our comments, we may
ask you to
provide us with information so we may better understand your disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to these comments, we may have additional
comments.

Form 10-K for fiscal year ended December 31, 2018

Notes to Consolidated Financial Statements
Note 5, Collaboration Agreements, page F-15

1.    Please provide us the following terms governing the Takeda collaboration,
as well as your
      consideration of providing additional disclosure pursuant to ASC
606-10-50.
        Quantify the amount allocated to each performance obligation.
        Describe and quantify the methods and assumptions used to determine
standalone
          selling price for each collaboration.
        Provide a range of milestone and other payment obligations to be
received by stage
          (e.g. development, regulatory and commercialization). Also, tell us
your
          consideration of disclosing individually material milestones.
        It appears that the amount paid by Takeda for the purchase of 1,096,892
shares
          included a premium over the fair value of your stock on the date of
purchase. Clarify
 Keith Regnante
Wave Life Sciences Ltd.
November 26, 2019
Page 2
              how you accounted for the premium.
2.       Please provide us the following information regarding licenses that
you received under
         your collaboration agreements with Pfizer and Takeda and your
consideration of
         providing additional disclosure under ASC 606.
           Provide a range of future milestone obligations by stage that you
may be required to
             pay to Pfizer and Takeda (e.g. development, regulatory and
commercialization).
           Tell us your consideration of including disclosure relating to your
obligations on page
             95 under the Contractual Obligation Table.
           Provide a description and quantification of other possible future
obligations that you
             may be required to pay under these two collaboration agreements.
           Explain your basis for excluding discussion of governance by a joint
steering
             committee, as described in the Takeda collaboration agreement.
Also, tell us your
             consideration of including your obligations under the joint
steering committee as a
             separate performance obligation.
3.       You state on page F-18 that at December 31, 2018, deferred revenue
under the Takeda
         agreement was $160.4 million, of which $94.1 million was included in
current liabilities.
         At September 30, 2019, deferred revenue under this agreement was
$152.8 million, of
         which $93.6 million was included in current liabilities, while revenue
recognized for the
         nine months ended September 30, 2019 was $17.2 million. Please
demonstrate for us how
         revenue recognized was consistent with the expected research term
governing each
         performance obligation, including how associated incurred FTE hours
compared to total
         expected FTE hours. Also, provide us additional information for each
collaboration that
         will facilitate an understanding of the nature, timing and uncertainty
of revenue
         recognized to date and to be recognized in future periods.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       You may contact Frank Wyman at 202-551-3660 or Mary Mast at 202-551-3613
with
any questions.



FirstName LastNameKeith Regnante                             Sincerely,
Comapany NameWave Life Sciences Ltd.
                                                             Division of
Corporation Finance
November 26, 2019 Page 2                                     Office of Life
Sciences
FirstName LastName